{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:46:34Z","timestamp":1791049594560,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The pharmacology, microbiology, pharmacokinetics, pharmacodynamics, efficacy, safety, and role of ibrexafungerp in the treatment of fungal infections are reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Ibrexafungerp is the first triterpenoid antifungal. Similarly to echinocandins, it inhibits the synthesis of 1,3-\u03b2-d-glucan. However, it binds to a different site on the enzyme than echinocandins, resulting in limited cross-resistance. Ibrexafungerp exerts concentration-dependent fungicidal activity against Candida species and retains in vitro activity against most fluconazole-resistant strains. It is also active against Aspergillus species. Ibrexafungerp has been shown to be safe and effective in the treatment of vulvovaginal candidiasis caused by Candida albicans in phase 2 and phase 3 clinical trials. It is approved for vulvovaginal candidiasis in adult and postmenarchal pediatric females and is given as two 150-mg tablets orally, administered 12 hours apart. Ibrexafungerp is contraindicated in pregnancy. The most commonly reported adverse reactions were diarrhea, nausea, abdominal pain, dizziness, and vomiting. Ibrexafungerp should be avoided with strong or moderate CYP3A inducers, and the dose should be reduced with strong CYP3A inhibitors. Ibrexafungerp may be useful for patients who are not able to receive fluconazole or prefer oral therapy for the treatment of vulvovaginal candidiasis. However, it is more expensive than the 150-mg tablet of generic fluconazole, which is the current standard of care for vulvovaginal candidiasis. Clinical trials are ongoing for recurrent and complicated vulvovaginal candidiasis as well as invasive candidiasis and pulmonary aspergillosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Ibrexafungerp is an alternative to fluconazole for the treatment of vulvovaginal candidiasis in nonpregnant females. It has the potential to be useful for recurrent and complicated vulvovaginal candidiasis as well as certain invasive fungal infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac256","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:05:47Z","timestamp":1662768347000},"page":"2208-2221","source":"Crossref","is-referenced-by-count":20,"title":["Ibrexafungerp: A new triterpenoid antifungal"],"prefix":"10.1093","volume":"79","author":[{"given":"Allana J","family":"Sucher","sequence":"first","affiliation":[{"name":"Regis University School of Pharmacy , Denver, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Thai","sequence":"additional","affiliation":[{"name":"Regis University School of Pharmacy , Denver, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Tran","sequence":"additional","affiliation":[{"name":"Regis University School of Pharmacy , Denver, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netra","family":"Mantena","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University Gregory School of Pharmacy , West Palm Beach, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allwyn","family":"Noronha","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University Gregory School of Pharmacy , West Palm Beach, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B","family":"Chahine","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University Gregory School of Pharmacy , West Palm Beach, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"issue":"1","key":"2022120508524689700_CIT0001","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"2022120508524689700_CIT0002","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022120508524689700_CIT0003","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Centers for Disease Control and Prevention.","year":"2019"},{"issue":"suppl 6","key":"2022120508524689700_CIT0004","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2022120508524689700_CIT0005","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2022120508524689700_CIT0006","author":"Centers for Disease Control and Prevention."},{"key":"2022120508524689700_CIT0007","author":"Centers for Disease Control and Prevention."},{"key":"2022120508524689700_CIT0008","author":"Centers for Disease Control and Prevention."},{"key":"2022120508524689700_CIT0009","author":"Scynexis","year":"2021"},{"issue":"9","key":"2022120508524689700_CIT0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics"},{"issue":"3","key":"2022120508524689700_CIT0011","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J Fungi."},{"key":"2022120508524689700_CIT0012","volume-title":"Package insert","author":"Brexafemme","year":"2021"},{"issue":"9","key":"2022120508524689700_CIT0013","doi-asserted-by":"crossref","first-page":"e00833","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2022120508524689700_CIT0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antibiotics9060312","article-title":"Candidiasis and mechanisms of antifungal resistance","volume":"9","author":"Bhattacharya","year":"2020","journal-title":"Antibiotics"},{"key":"2022120508524689700_CIT0015","author":"Scynexis","year":"2018"},{"issue":"4","key":"2022120508524689700_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"2022120508524689700_CIT0017","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3109\/1040841X.2015.1091805","article-title":"Vulvovaginal candidiasis: epidemiology, microbiology and risk factors","volume":"42","author":"Gon\u00e7alves","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"2022120508524689700_CIT0018","doi-asserted-by":"crossref","first-page":"642358","DOI":"10.3389\/fcimb.2021.642358","article-title":"Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata","volume":"11","author":"Gamal","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"2022120508524689700_CIT0019","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"2022120508524689700_CIT0020","author":"Scynexis"},{"issue":"5","key":"2022120508524689700_CIT0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"issue":"9","key":"2022120508524689700_CIT0022","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1111\/1462-2920.14333","article-title":"Enfumafungin synthase represents a novel lineage of fungal triterpene cyclases","volume":"20","author":"Kuhnert","year":"2018","journal-title":"Environ Microbiol"},{"key":"2022120508524689700_CIT0023","doi-asserted-by":"crossref","first-page":"127661","DOI":"10.1016\/j.bmcl.2020.127661","article-title":"Ibrexafungerp: an orally active \u03b2-1,3-glucan synthesis inhibitor","volume":"32","author":"Apgar","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"2022120508524689700_CIT0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0723-2020(00)80062-4","article-title":"The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species: biological activity and taxonomy of the producing organisms","volume":"23","author":"Pel\u00e1ez","year":"2000","journal-title":"Syst Appl Microbiol"},{"issue":"3","key":"2022120508524689700_CIT0025","doi-asserted-by":"crossref","first-page":"e01961","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2022120508524689700_CIT0026","doi-asserted-by":"crossref","first-page":"e00244","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2022120508524689700_CIT0027","doi-asserted-by":"crossref","first-page":"e0056221","DOI":"10.1128\/AAC.00562-21","article-title":"In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida isolates from women with vulvovaginal candidiasis","volume":"65","author":"Sobel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120508524689700_CIT0028","year":"2021"},{"issue":"3","key":"2022120508524689700_CIT0029","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/jof7030232","article-title":"In vitro activity of ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies","volume":"7","author":"Rivero-Menendez","year":"2021","journal-title":"J Fungi"},{"issue":"7","key":"2022120508524689700_CIT0030","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jac\/dkaa102","article-title":"A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method","volume":"75","author":"Meletiadis","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2022120508524689700_CIT0031","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2022120508524689700_CIT0032","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2022120508524689700_CIT0033","doi-asserted-by":"crossref","first-page":"e01102","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2022120508524689700_CIT0034","doi-asserted-by":"crossref","first-page":"e01692","DOI":"10.1128\/AAC.01692-19","article-title":"In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2022120508524689700_CIT0035","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2022120508524689700_CIT0036","doi-asserted-by":"crossref","first-page":"e02136","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2022120508524689700_CIT0037","doi-asserted-by":"crossref","first-page":"e00435","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2022120508524689700_CIT0038","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2022120508524689700_CIT0039","doi-asserted-by":"crossref","first-page":"e02119","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2022120508524689700_CIT0040","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2022120508524689700_CIT0041","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120508524689700_CIT0042"},{"key":"2022120508524689700_CIT0043","author":"Scynexis.","year":"2016"},{"issue":"12","key":"2022120508524689700_CIT0044","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2022120508524689700_CIT0045","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2022120508524689700_CIT0046","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"2022120508524689700_CIT0047"},{"key":"2022120508524689700_CIT0048"},{"key":"2022120508524689700_CIT0049"},{"key":"2022120508524689700_CIT0050","author":"Scynexis","year":"2022"},{"key":"2022120508524689700_CIT0051"},{"key":"2022120508524689700_CIT0052"},{"key":"2022120508524689700_CIT0053","author":"Scynexis","year":"2022"},{"key":"2022120508524689700_CIT0054","author":"Scynexis","year":"2022"},{"key":"2022120508524689700_CIT0055"},{"key":"2022120508524689700_CIT0056"},{"issue":"10","key":"2022120508524689700_CIT0057","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2022120508524689700_CIT0058","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2022120508524689700_CIT0059","volume-title":"Red Book Online [proprietary data]","author":"Brexafemme","year":"2022"},{"key":"2022120508524689700_CIT0060","volume-title":"Red Book Online [proprietary data]","author":"Fluconazole","year":"2022"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac256\/45968399\/zxac256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/24\/2208\/47562219\/zxac256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/24\/2208\/47562219\/zxac256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T08:53:09Z","timestamp":1670230389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/24\/2208\/6694926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":60,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,9,9]]},"published-print":{"date-parts":[[2022,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac256","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,15]]},"published":{"date-parts":[[2022,9,9]]}}}